Review



13(s)-hode-d4 standard  (Cayman Chemical)


Bioz Verified Symbol Cayman Chemical is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cayman Chemical 13(s)-hode-d4 standard
    13(s) Hode D4 Standard, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/13(s)-hode-d4 standard/product/Cayman Chemical
    Average 90 stars, based on 1 article reviews
    13(s)-hode-d4 standard - by Bioz Stars, 2026-06
    90/100 stars

    Images



    Similar Products

    hydroxy 9z 11e octadecadienoic acid 13s and 13r hode  (Larodan)
    90
    Larodan hydroxy 9z 11e octadecadienoic acid 13s and 13r hode
    Hydroxy 9z 11e Octadecadienoic Acid 13s And 13r Hode, supplied by Larodan, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hydroxy 9z 11e octadecadienoic acid 13s and 13r hode/product/Larodan
    Average 90 stars, based on 1 article reviews
    hydroxy 9z 11e octadecadienoic acid 13s and 13r hode - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    13 hode  (Proteintech)
    93
    Proteintech 13 hode
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    13 Hode, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/13 hode/product/Proteintech
    Average 93 stars, based on 1 article reviews
    13 hode - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    13(s)-hode-d4 standard  (Cayman Chemical)
    90
    Cayman Chemical 13(s)-hode-d4 standard
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    13(s) Hode D4 Standard, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/13(s)-hode-d4 standard/product/Cayman Chemical
    Average 90 stars, based on 1 article reviews
    13(s)-hode-d4 standard - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    hode: 13(s)-hydroxy-octadecadienoic acid-d4  (Cayman Chemical)
    90
    Cayman Chemical hode: 13(s)-hydroxy-octadecadienoic acid-d4
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    Hode: 13(s) Hydroxy Octadecadienoic Acid D4, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hode: 13(s)-hydroxy-octadecadienoic acid-d4/product/Cayman Chemical
    Average 90 stars, based on 1 article reviews
    hode: 13(s)-hydroxy-octadecadienoic acid-d4 - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    13(s)-hode-d4  (Cayman Chemical)
    90
    Cayman Chemical 13(s)-hode-d4
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    13(s) Hode D4, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/13(s)-hode-d4/product/Cayman Chemical
    Average 90 stars, based on 1 article reviews
    13(s)-hode-d4 - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    13(s)-hode gc19463  (GlpBio Technology Inc)
    90
    GlpBio Technology Inc 13(s)-hode gc19463
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    13(s) Hode Gc19463, supplied by GlpBio Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/13(s)-hode gc19463/product/GlpBio Technology Inc
    Average 90 stars, based on 1 article reviews
    13(s)-hode gc19463 - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    acid 13 s hode  (Proteintech)
    95
    Proteintech acid 13 s hode
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    Acid 13 S Hode, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/acid 13 s hode/product/Proteintech
    Average 95 stars, based on 1 article reviews
    acid 13 s hode - by Bioz Stars, 2026-06
    95/100 stars
    		  Buy from Supplier
    13-hydroxy-9z,11e-octadecadienoic acid, cholesteryl ester (13- hode-ce)  (Cayman Chemical)
    90
    Cayman Chemical 13-hydroxy-9z,11e-octadecadienoic acid, cholesteryl ester (13- hode-ce)
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    13 Hydroxy 9z,11e Octadecadienoic Acid, Cholesteryl Ester (13 Hode Ce), supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/13-hydroxy-9z,11e-octadecadienoic acid, cholesteryl ester (13- hode-ce)/product/Cayman Chemical
    Average 90 stars, based on 1 article reviews
    13-hydroxy-9z,11e-octadecadienoic acid, cholesteryl ester (13- hode-ce) - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    9 12 13 s s s trihydroxyoctadec 10eenoic acid  (Larodan)
    94
    Larodan 9 12 13 s s s trihydroxyoctadec 10eenoic acid
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    9 12 13 S S S Trihydroxyoctadec 10eenoic Acid, supplied by Larodan, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/9 12 13 s s s trihydroxyoctadec 10eenoic acid/product/Larodan
    Average 94 stars, based on 1 article reviews
    9 12 13 s s s trihydroxyoctadec 10eenoic acid - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    9 10 13 s s s trihydroxyoctadec 11e enoic acid  (Larodan)
    94
    Larodan 9 10 13 s s s trihydroxyoctadec 11e enoic acid
    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing <t>increased</t> <t>13-HODE</t> levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5
    9 10 13 S S S Trihydroxyoctadec 11e Enoic Acid, supplied by Larodan, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/9 10 13 s s s trihydroxyoctadec 11e enoic acid/product/Larodan
    Average 94 stars, based on 1 article reviews
    9 10 13 s s s trihydroxyoctadec 11e enoic acid - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing increased 13-HODE levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5

    Journal: Molecular Cancer

    Article Title: Targeting OxLDL-mediated CD36 + CAF reprogramming potentiates PD-1 immunotherapy in osteosarcoma

    doi: 10.1186/s12943-025-02516-2

    Figure Lengend Snippet: PPARG-mediated lipid metabolism reprograms CD36⁺ CAFs through the CD36–FABP4 axis. a – d PPARG activity and expression in CAFs, showing positive correlations with CD36 and FABP4. e – f qRT-PCR validation of PPARG, CD36, and FABP4 expression in ( e ) CD36⁺ CAFs ( n = 5 per group, ** p < 0.01) and ( f ) in response to OxLDL treatment (50 µg/mL; n = 3 per group, ** p < 0.01, * p < 0.05). g Western blot analysis of CD36, PPARG, ANGPTL4, and FABP4 expression in CAFs treated with OxLDL, siCD36, or CD36 inhibitor (SSO) ( n = 3 per group). h – i qRT-PCR and Western blot showing that PPARG knockdown reduces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05). j ChIP-qPCR confirming PPARG binding to CD36 and FABP4 promoters ( n = 3 per group, ** p < 0.01, * p < 0.05). k ELISA showing increased 13-HODE levels in CAFs after OxLDL stimulation ( n = 3 per group, *** p < 0.001). (l–m) qRT-PCR and Western blot showing that 13-HODE induces CD36, FABP4, and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). n – o qRT-PCR and Western blot showing that FABP4 knockdown impairs 13-HODE–induced CD36 and ANGPTL4 expression ( n = 5 per group, **** p < 0.0001, *** p < 0.001). p Molecular docking analysis predicting binding interactions among 13-HODE, FABP4, and the PPARG ligand-binding domain (LBD). q – r AlphaFold modeling, and co-IP validating FABP4–PPARG interaction. See also Supplementary Figure S5

    Article Snippet: Blood samples were collected from cardiac puncture separated by centrifugation at 3000 g, 4°C, 10 min. OxLDL (Elabscience, E-EL-M0066), 13-HODE (MEIMIAN, MM-60095H2) and ANGPTL4 (Proteintech, KE00186) levels were measured using ELISA kits following the manufacturer’s instructions.

    Techniques: Activity Assay, Expressing, Quantitative RT-PCR, Biomarker Discovery, Western Blot, Knockdown, ChIP-qPCR, Binding Assay, Enzyme-linked Immunosorbent Assay, Ligand Binding Assay, Co-Immunoprecipitation Assay